BIRC5 and renal cell carcinoma: Similar results were observed in both RCC cell lines after treatment with DIM-C-pPhOH (Fig 4B) or DIM-C-pPhCO2Me (Fig 4C), confirming that the NR4A1 antagonists inhibited NR4A1-regulated expression of survivin, bcl-2 and EGFR in ACHN and 786-O cells as previously reported in pancreatic, lung and colon cancers [14–17].